Examination of the usefulness and safety of a self-propelling capsule endoscope for observing the digestive tract

Examination of the usefulness and safety of a self-propelling capsule endoscope for observing the digestive tract - Examination of the usefulness and safety of a self-propelling capsule endoscope for observing the digestive tract

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027805

Enrollment

Registered

2017-07-01

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

screening

Interventions

The digestive tract will be examined using a self-propelling capsule endoscope according to the following methods: As pretreatment, 24 mg of sennoside will be orally administered at 21:00 the day bef

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy adults, aged more than 20 years, from whom informed consent regarding participation in this study was obtained.

Exclusion criteria

Exclusion criteria: Exclusion criteria for capsule endoscopy will be adopted (1) Persons in whom nausea vomiting and abdominal distension suggest the presence of gastrointestinal occlusion or stenosis (2) Those with a history of gastrointestinal diseases, such as Crohn s disease (3) Those with a history of abdominal surgery (4) Those with a history of pelvic radiotherapy (5) Those wearing a cardiac pacemaker or other electric medical devices (6) Those with dysphagia (7) Those regularly taking NSAIDs

Design outcomes

Primary

Measure	Time frame
Emptying time for each section of the digestive tract (stomach, small intestine, large intestine)	—

Secondary

Measure	Time frame
Detection of lesions, degree of intestinal lavage, and presence or absence of adverse events	—

Countries

Japan

Contacts

Public ContactSadaharu Nouda

Osaka Medical College Second Department of Internal Medicine

sadaharu.nouda.1110@hotmail.co.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026